CytRx Corporation  

(Public, NASDAQ:CYTR)   Watch this stock  
Find more results for CHERYL LOUIS´┐Ż
0.620
+0.017 (2.85%)
After Hours: 0.620 0.000 (0.00%)
Jul 28, 4:59PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 0.59 - 0.62
52 week 0.55 - 3.66
Open 0.62
Vol / Avg. 1.67M/3.71M
Mkt cap 59.52M
P/E     -
Div/yield     -
EPS -0.85
Shares 123.72M
Beta 1.66
Inst. own 17%
Aug 1, 2016
Q2 2016 CytRx Corp Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Jul 12, 2016
CytRx Corp Annual Shareholders Meeting
Jul 11, 2016
CytRx Corporation Update Call
Jun 7, 2016
CytRx Corp at Jefferies Healthcare Conference
May 11, 2016
Q1 2016 CytRx Corp Earnings Release
May 5, 2016
CytRx Corp at Joseph Gunnar PIONEERS Conference
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin - -58587.19%
Operating margin - -63278.13%
EBITD margin - -62960.48%
Return on average assets -71.24% -76.73%
Return on average equity -130.60% -104.63%
Employees 31 -
CDP Score - -

Address

11726 San Vicente Blvd Ste 650
LOS ANGELES, CA 90049-5079
United States - Map
+1-310-8265648 (Phone)
+1-310-8266139 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

CytRx Corporation is a biopharmaceutical research and development company specializing in oncology. The Company is focused on the clinical development of aldoxorubicin, its modified version of the chemotherapeutic agent, doxorubicin. It is engaged in Phase III trials for aldoxorubicin as a therapy for patients with soft tissue sarcoma (STS) whose tumors have progressed after treatment with chemotherapy. It is also involved in evaluating aldoxorubicin in a Phase IIb clinical trial in small cell lung cancer; a Phase II clinical trial in human immunodeficiency virus-related Kaposi's sarcoma; a Phase II clinical trial in patients with late-stage glioblastoma (brain cancer); a Phase Ib trial in combination with ifosfamide in patients with STS, and a Phase Ib trial in combination with gemcitabine in subjects with metastatic solid tumors. It is engaged in the pre-clinical development for DK049, an anti-cancer drug conjugate that utilizes its Linker Activated Drug Release (LADR) technology.

Officers and directors

John Y Caloz Chief Financial Officer
Age: 63
Bio & Compensation  - Reuters
Daniel J Levitt M.D., Ph.D. Executive Vice President, Chief Medical Officer
Age: 67
Bio & Compensation  - Reuters
Douglas Scott Wieland Ph.D. Senior Vice President - Drug Development
Age: 56
Bio & Compensation  - Reuters
David J. Haen Vice President - Business Development
Age: 37
Bio & Compensation  - Reuters
Olivia C. Ware Chief Commercial Officer
Bio & Compensation  - Reuters
Steven A. Kriegsman Chairman of the Board, President, Chief Executive Officer
Age: 73
Bio & Compensation  - Reuters
Joseph Rubinfeld Ph.D. Lead Independent Director
Age: 83
Bio & Compensation  - Reuters
Cheryl L. Cohen Director
Age: 49
Bio & Compensation  - Reuters
Anita J. Chawla Ph.D. Independent Director
Age: 56
Bio & Compensation  - Reuters
Louis J. Ignarro Ph.D. Independent Director
Age: 73
Bio & Compensation  - Reuters